Home / Business and Economy / Aurobindo Pharma Ties Up With STADA for EU Biosimilars
Aurobindo Pharma Ties Up With STADA for EU Biosimilars
25 Mar
Summary
- Aurobindo's CuraTeQ partners with STADA for EU biosimilar distribution.
- Two EMA-approved biosimilars will be marketed in select EU nations.
- USFDA inspection of Aurobindo's Telangana facility closed with VAI status.
Hyderabad-based Aurobindo Pharma revealed on March 25, 2026, that its subsidiary CuraTeQ Biologics has entered a strategic marketing and distribution pact with STADA Arzneimittel AG. This collaboration focuses on biosimilars within specified territories of the European Union.
The agreement empowers STADA to market and distribute two biosimilars developed by CuraTeQ, both of which have secured approval from the European Medicines Agency (EMA). These biosimilars will be introduced in key EU markets, including France and Germany, under newly registered brand names.
In related news, Aurobindo Pharma's subsidiary Apitoria Pharma Pvt Ltd received a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA). This classification pertains to its Unit-V manufacturing facility in Telangana, following an inspection conducted between December 1 and December 12, 2025.
The VAI status signifies that the USFDA inspection is officially closed. While some observations were noted during the inspection, they are not considered significant enough to trigger regulatory or enforcement actions by the USFDA, marking a positive development for the facility.
